N0550000

Neostigmine methyl sulfate

Name: Neostigmine methyl sulfate
Brand: SIAL
Price: 2655.8 ZAR

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate

Slide 1 of 1

Select a Size

50 MG

R 2,655.80

List PriceR 2,710.00

Please contact Customer Service for Availability

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):

C₁₃H₂₂N₂O₆S

CAS Number:

51-60-5

Molecular Weight:

334.39

NACRES:

NA.24

PubChem Substance ID:

329818445

UNSPSC Code:

41116107

MDL number:

MFCD00011796

Key Documents

View All Documentation

Product Name

Neostigmine methyl sulfate, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C12H19N2O2.CH4O4S/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;1-5-6(2,3)4/h6-9H,1-5H3;1H3,(H,2,3,4)/q+1;/p-1

SMILES string

COS([O-])(=O)=O.CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C

InChI key

OSZNNLWOYWAHSS-UHFFFAOYSA-M

grade

pharmaceutical primary standard

API family

neostigmine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ACHE(43)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Chemistry

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Reference Materials

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	1460000	N2126	N0500000
N0550000 Neostigmine methyl sulfate	USP 1460000 Neostigmine methyl sulfate	Sigma-Aldrich N2126 Neostigmine methyl sulfate	N0500000 Neostigmine bromide
manufacturer/tradename EDQM	manufacturer/tradename USP	manufacturer/tradename -	manufacturer/tradename EDQM
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade -	grade pharmaceutical primary standard
format neat	format neat	format -	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) -	application(s) pharmaceutical (small molecule)
API family neostigmine	API family neostigmine	API family -	API family neostigmine
Gene Information human ... ACHE(43)	Gene Information human ... ACHE(43)	Gene Information human ... ACHE(43)	Gene Information human ... ACHE(43)

Application

Neostigmine methyl sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.

Reversible inhibitor of acetylcholinesterase; does not cross the blood-brain barrier.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

related product

Product No.

Description

Pricing

N0500000

Neostigmine bromide, European Pharmacopoeia (EP) Reference Standard

1460000

Neostigmine methyl sulfate, United States Pharmacopeia (USP) Reference Standard

1459001

Neostigmine bromide, United States Pharmacopeia (USP) Reference Standard

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H300,H315,H319,H334,H335

pcodes

P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 2 Oral - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Medical and surgical treatment for ocular myasthenia.

Michael Benatar et al.

The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)

Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review

Analgesic effect of intrathecal neostigmine combined with bupivacaine and fentanyl.

M O Akinwale et al.

African journal of medicine and medical sciences, 41(2), 231-237 (2012-11-29)

The spinal route of analgesia has consolidated its place as a major modality in the management of both acute and chronic pain. The search for ideal additives to local anaesthetic agents to prolong the analgesic effects poses a challenge to

[Anticholinesterases; peripheral and central effects].

Tetsufumi Sato et al.

Masui. The Japanese journal of anesthesiology, 62(1), 19-26 (2013-02-26)

Anticholinesterase, such as neostigmine, was used to be a standard drug at the end of surgery for reversal of nondepolarizing neuromuscular block. Neostigmine decreases the metabolism of acetylcholine (ACh) at the neuromuscular junction and allows its concentration to increase and

A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery.

G V Cammu et al.

Anaesthesia and intensive care, 40(6), 999-1006 (2012-12-01)

Six years ago, a study performed in our department reported that the incidence of postoperative residual curarisation (PORC) was 39%. The reassessment of neuromuscular monitoring and reversal of neuromuscular block in routine anaesthetic practice is relevant now that sugammadex has

New neostigmine-based behavioral mouse model of abdominal pain.

Jakub Fichna et al.

Pharmacological reports : PR, 64(5), 1146-1154 (2012-12-15)

Animal models of visceral pain have gained much attention as an important tool to elucidate the possible mechanisms underlying functional gastrointestinal (GI) disorders. Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service